Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SLXN
SLXN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SLXN News
Silexion Finishes Toxicology Studies for SIL204; Phase 2/3 Trial for Pancreatic Cancer Set to Start in Q2
Nov 26 2025
NASDAQ.COM
Silexion Completes Toxicology Studies for SIL204, Plans Phase 2/3 Trial in 2026
Nov 25 2025
Newsfilter
Silexion Therapeutics Meets Nasdaq Listing Standards Again
Sep 25 2025
Newsfilter
Silexion Therapeutics Stock Rises Following Encouraging Preclinical Results for Pancreatic Cancer
Sep 11 2025
Benzinga
What’s Behind the 190% Surge in Silexion Therapeutics Stock (SLXN) Today?
Sep 11 2025
TipRanks
Silexion Therapeutics Shares Encouraging Preclinical Findings on SIL204's Effectiveness and Distribution in Key Metastatic Sites of Pancreatic Cancer After Systemic Delivery
Sep 11 2025
Newsfilter
Silexion Therapeutics Chooses Contract Research Organization to Assist with Upcoming Phase 2/3 Clinical Trials for SIL204
Sep 04 2025
Newsfilter
Crude Oil Down 2%; Amazon Shares Tumble After Q2 Results
Aug 01 2025
Benzinga
Nasdaq Dips Over 2%; Apple Earnings Top Views
Aug 01 2025
Benzinga
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Aug 01 2025
Newsfilter
Why Is Silexion Therapeutics Stock Trading Higher On Thursday?
Jul 31 2025
Benzinga
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation
Jul 31 2025
Newsfilter
Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested
Jul 27 2025
TipRanks
Silexion Therapeutics Announces 1-for-15 Reverse Share Split
Jul 16 2025
Newsfilter
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Jun 02 2025
Benzinga
Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers
May 29 2025
Newsfilter
Show More News
